The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Multispecialty Team Approach Key to Diagnosing, Treating Neutrophilic Dermatosis

Multispecialty Team Approach Key to Diagnosing, Treating Neutrophilic Dermatosis

February 15, 2017 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

WASHINGTON, D.C.—Often, no clear explanation exists in neutrophilic dermatosis cases that links a patient’s skin disorder with an internal condition, expert Joseph Jorizzo, MD, professor, founder and former chair of the Dermatology Department at Wake Forest University in Winston-Salem, N.C., and professor of clinical dermatology at Wevascularill Cornell Medical College in New York, told attendees in the 2016 ACR/ARHP Annual Meeting session titled, Neutrophilic Dermatoses.

You Might Also Like
  • Tips for Diagnosing, Treating Seldom Seen Forms of Vasculitis
  • Diagnosing, Treating IgG4-Related Disease
  • A Case Study in Sweet’s Syndrome with Pulmonary Involvement
Explore This Issue
February 2017
Also By This Author
  • Digital Healthcare Devices, Sensors Gaining Ground as Portable Personal Coaches

Neutrophilic Vascular Reactions

“One of the things I want to really highlight,” Dr. Jorizzo said, “is the difference between the kind of dermatoses where a clinical pathologic diagnosis ties together the patient’s internal complaints and their cutaneous findings, such as sarcoidosis or lupus or dermatomyositis, and focus on a prime category of reactive dermatoses.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

About half of patients in the “reactive” category will have no underlying disease, he said. The others may have a process that is caused by a reaction to a rheumatologic, gastroenterologic or myelodysplastic condition, or some other disorder.

“So [reactive diseases] require even more teamwork among colleagues than do the other diseases, where you just walk in, and the skin and inside is all together,” Dr. Jorizzo said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

These diseases, described as “neutrophilic vascular reactions” in a 1988 paper led by Dr. Jorizzo, include Sweet’s syndrome, Behçet’s disease, bowel-associated dermatosis-arthritis syndrome and pyoderma gangrenosum.1

“I like to include the word vascular, because I believe the neutrophilic process is vessel based, primarily, and that distinguishes this from diseases where the epidermis is the target, such as psoriasis,” Dr. Jorizzo said.

The biopsy is a crucial element in the diagnosis of these diseases, but getting one that’s actually helpful is not a simple proposition, he added.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“There’s a certain art in delivering to the pathologist [that which] gives you a chance of getting the diagnosis,” he said. “You want a lesion that’s just far enough advanced to have the classic changes, but not so far advanced that those changes are masked by secondary change.”

He also emphasized the concept of a therapeutic ladder—that the intensity of a therapy and the risk that’s willing to be tolerated—should be capped based on the extent of the disease.

Sweet’s Syndrome

Sweet’s syndrome involves fever and malaise, along with erythematous plaques on clinical exam. Histologically, its traits include dense perivascular neutrophilic leukocytoclasia with minimal, or even no, evidence of vasculitis. Associated conditions can include infections, malignancies, inflammatory bowel disease and autoimmune disorders.

Dr. Jorizzo said thalidomide is often his preferred treatment for Sweet’s syndrome. This prescribed treatment can sometimes cause difficulties with health insurance companies because they might want an oncologist to approve the medication. Dr. Jorizzo mentioned a patient with whom this was the case. When the oncologist balked at the request, he sent the patient to him with a severe case of Sweet’s on the face, at which point the oncologist signed off right away.

Behçet’s Disease

Behçet’s is a multisystem disease with many symptoms. Skin findings range from sterile papulopustules and palpable purpura to erythema nodosum-like lesions. On histology, a neutrophilic infiltrate will be seen, with leukocytoclastic vasculitis early in the disease course and lymphocytic vasculitis late in the course.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: 2016 ACR/ARHP Annual Meeting, Arthritis, Behçet’s disease, bowel, dermatosis, Diagnosis, neutrophilic vascular reactions, reactive disease, rheumatologist, rheumatology, Sweet's syndrome, TreatmentIssue: February 2017

You Might Also Like:
  • Tips for Diagnosing, Treating Seldom Seen Forms of Vasculitis
  • Diagnosing, Treating IgG4-Related Disease
  • A Case Study in Sweet’s Syndrome with Pulmonary Involvement
  • Dermatology Case Answer: History of ANCA–Associated Vasculitis, Fever, Rash

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)